Patient Death in China Gene-Editing Trial Raises Alarms Over Regulatory Oversight and Transparency
核心洞察
A 6-year-old girl died in March 2025 from a severe immune reaction after receiving an experimental base-editing therapy at Shanghai Xinhua Hospital (搜索), a death that was never publicly disclosed.
The family paid more than $860,000 to fund the therapy's development, a financial arrangement omitted from the Nature (搜索) paper detailing preclinical animal studies.
Seven independent experts who reviewed the case expressed concern that safety signals in animal studies were overlooked and that the trial should not have proceeded.
A 6-year-old girl died in March 2025 at Shanghai Xinhua Hospital (搜索) after receiving an experimental gene-editing therapy in a clinical trial whose fatal outcome was never publicly reported, according to a joint investigation by Science and Retraction Watch. The case has drawn sharp criticism from experts who say safety signals were ignored, risks were downplayed, and the regulatory framework governing such investigator-initiated trials in China remains dangerously opaque.
The girl, who had a rare genetic mutation affecting her neurodevelopment, was the sole patient in a trial designed to correct a single mutated DNA base — a T that should have been a C — using base editing, a more precise form of CRISPR gene editing. Seven days after her medical team infused trillions of viruses carrying the base editor into her spinal fluid, she died of a severe immune reaction linked to the therapy.
Financial arrangements and missing disclosures
The family contributed $860,000 — scraped together from personal savings and relatives — to fund the therapy's development and clinical work. This financial arrangement was absent from the Nature (搜索) paper published earlier in 2026 that detailed proof-of-concept animal studies related to the trial. The paper also omitted troubling kidney and liver issues that emerged in earlier monkey experiments, according to the Science investigation.
The girl's parents have now come forward, angered by what they describe as a lack of accountability. "Learning the reality of these missing safeguards has fundamentally changed how we now view the entire project," said the father, a software engineer. "We did not realize how unusual and dangerous many of the arrangements were."
The parents have asked the authors to withdraw the Nature (搜索) paper, and several experts who reviewed the case say the issues may warrant a retraction.
Expert concerns over safety signals
Seven experts in genetics, virology, and bioethics who reviewed details of the Nature (搜索) study and the clinical trial expressed concern that the research team, led by neuroscientist Zilong Qiu of Shanghai Jiao Tong University School of Medicine (搜索), downplayed the trial's risks when describing them to the parents, overlooked safety signals in animal studies, and proceeded despite a low likelihood of success.
"This shouldn't have gone to trial," said Steven Gray of the University of Texas Southwestern Medical Center, who develops viruses for gene therapy. Gray and several other experts are calling for a full review of images and data in the Nature (搜索) paper and full disclosure of the study's funding.
Neither Qiu, nor physician Yongguo Yu — who oversaw the study — nor Xinhua Hospital responded to multiple requests for comment. Nature (搜索) stated it was not aware of the issues surrounding the clinical trial before publishing the group's paper.
Regulatory gaps in China's IIT system
The trial proceeded under China's investigator-initiated trial (IIT) pathway, a regulatory provision that allows researchers at major hospitals to test novel therapies after local review, without requiring approval from the national drug regulator. Such studies have surged in recent years, growing 11-fold from 2015 to 2023 to surpass 1,000.
The hospital was fined approximately $3,600 for its failures in the trial, and Yu received verbal counseling. The family was offered no compensation.
"This shows the gap between what is intended and what has been put in place," said Joy Zhang, a sociologist at the University of Kent who has written about the culture of secrecy in Chinese scientific institutions.
In June, China revamped regulations around cell and gene therapy research, restricting cutting-edge trials to certain hospitals and banning institutions from charging patients fees related to clinical research. The reforms also outlined pathways for qualified hospitals to commercialize some advanced procedures without traditional drug registration.
The case echoes earlier controversies in Chinese biomedical research, most notably scientist He Jiankui's creation of the world's first genetically altered babies, which tested the balance between regulatory supervision and China's ambition to lead in biotechnology innovation.